NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
M.D. Anderson Cancer Center
Georgetown University
Children's Hospital Medical Center, Cincinnati
Novartis
Novartis
Novartis